Alzheimer's disease (AD) is a neurodegenerative age-related progressive disease and the most common cause of dementia in the elderly.
grows, the accompanying economic and psychosocial costs related to acute hospitalizations, nursing home care, and care-giver stress will also escalate. Therefore, it is not surprising that efforts to understand the pathophysiology of AD and thereby derive effective treatments for this devastating disease have never been greater.
Over the last few decades a great deal of information has been learned about the underlying cellular and molecular pathology of AD.
Since the early 1900s it has been recognized that the major pathologic hallmarks of AD are senile or neuritic plaques and neurofibrillary tangles, composed primarily of amyloid-beta (Aβ) peptide and hyperphosphorylated tau protein, respectively. 3 The pathologic consequences of these lesions are synaptic dysfunction, neuronal loss, and gross cerebral atrophy. 4 Several other AD-related pathologies have been identified, including inflammation and microvascular deposition of Aβ (also known as amyloid angiopathy). 4 These pathologic features are the targets of substantial drug development efforts that are aimed primarily at preventing the deposition of Aβ and/or abnormally phosphorylated tau, as described below.
Aβ Pathology
For at least two decades the primary focus of AD pathophysiology has been on the extracellular plaques containing a core of Aβ peptide that is 40-42 amino acids in length. Over the years a series of elegant studies have shown that the Aβ peptide is cleaved from a larger precursor molecule, the amyloid precursor protein (APP) (see Figure 1 ). 
Tau Pathology
In addition to deposition of Aβ in the form of senile plaques, the other major pathologic hallmark of AD is neurofibrillary tangles, which are composed of hyperphosphorylated tau. 3 Normally found in microtubules, tau protein plays an important role in microtubule stabilization. 11 It follows that tau indirectly regulates synaptic structure and function, which to a large extent are dependent on the integrity of microtubules. Evidence has shown that hyperphosphorylated tau dissociates from the microtubular network and forms intraneuronal aggregates that are neurotoxic. 
Other Potential Processes Contributing to Alzheimer's Disease Pathophysiology
In addition to the major pathologic features discussed above, several other intracellular processes may contribute to AD pathogenesis. As Other processes for which there is experimental evidence supporting a role in AD pathogenesis are mitochondrial dysfunction and oxidative stress. 16, 17 In addition to AD, oxidative stress and mitochondrial dysfunction can be demonstrated in many other neurodegenerative diseases. Further studies will be necessary to establish causative roles for these processes in AD pathophysiology.
Current and Future Therapeutics for Alzheimer's Disease
Given the complexity of pathogenesis in the AD brain and the multiple layers of pathology that exist, it is not surprising that effective therapies to treat or prevent the disease have proved elusive. AD is an age-related disease, suggesting that possibilities exist to prevent the occurrence of the disorder during the aging process. AD is characterized by extensive neuronal and synaptic loss, which is thought to occur as a consequence of the accumulation of synaptotoxic Aβ peptides and hyperphosphorylated tau tangles, and underlies the memory loss associated with the disease. As AD is ultimately characterized by neuronal and synaptic loss, treatment will fall into three main categories: symptomatic relief, neuronal/synaptic loss reversal, and disease modification.
Symptomatic relief agents compensate for some of the cognitive decline caused by the disease but do nothing to address the underlying disease progression of accumulation of pathologies and subsequent synaptic and neuronal loss. As such, they provide temporary relief against the disease but ultimately become overwhelmed by the underlying pathology.
Symptomatic relief therapies have been identified and are currently Less research is being undertaken in trying to reverse the synaptic neuronal loss, perhaps due to a lack of animal models that show neuronal loss, but some progress is being made with stem cell implantation 27 and neurotrophins. 28 Both of these approaches appear to promote synaptogenesis and recover learning and memory deficits in numerous transgenic mouse models, [27] [28] [29] However, these current modulators have low efficacy and have since failed in clinical trials. 35 Several companies are currently testing γ-secretase inhibitors in the clinic, and it is hoped that these new-generation inhibitors will have more specificity for APP and hence fewer side effects.
BACE is one of the primary targets for blocking generation of Aβ, and BACE inhibitors have also been developed. 36 BACE has no other known function in the adult brain, and BACE knockout mice are perfectly viable with few obvious deficits. 37 However, the large binding pocket of BACE combined with its membrane location have proved a challenge in designing effective inhibitors that can cross the blood-brain barrier in sufficient concentrations to be useful, and, to date, no effective compounds have been fully developed.
An alternate approach to prevent Aβ generation is to stimulate the cleavage of APP at different sites, which then preclude it from becoming a substrate for BACE. These pathways are known as nonamyloidogenic and, to date, a single non-amyloidogenic pathway has been described in detail whereby APP is cleaved by an α-secretase. In fact, the vast majority of APP molecules are cleaved by the α-secretase processing pathway rather than by BACE. Several α-secretases have been identified that cleave APP 83 amino acids from the C-terminal. 38 This cut exists within the Aβ sequence and thus precludes Aβ generation. It is possible to stimulate further α-secretase cleavage of APP using phorbol esters or M1 agonists, 39 leading to reductions in pathology in mouse models of the disease. Central nervous system (CNS) permeable M1 agonists as well as forms of retinoids that promote α-secretase processing of APP have been developed that could potentially be moved into the clinic. [40] [41] [42] Alternatively, rather than preventing the production of Aβ in the first place, it has been established that Aβ can be cleared from the brain via immunotherapy, aggregation blockers (i.e. plaque busters), or via modulation of the ApoE system. The most developed of these, and for that matter of any disease-modifying strategy, is immunotherapy. 43 It was first demonstrated in 1999 in an APP-overexpressing transgenic mouse that active immunization with Aβ led to robust clearance of plaques in the brain. 44 Since then, immunotherapy has been widely studied in mouse models of the disease, with both passive and active immunization proving effective. 45 Furthermore, it has been shown that removal of Aβ via immunotherapy also leads to the removal of tau pathologies in transgenic mice. 46 However, results of clinical trials have thus far been mixed, with meningoencephalitis occurring in a number of patients and no robust improvements in cognition. 47 Despite analyses showing statistically significant reductions in plaque load, 48 the lack of effects on cognition may be because immunotherapy does nothing to address the existing loss of both synapses and neurons. Hence, immunotherapy (and any Aβ-targeting strategy) may prove to be a powerful way to prevent the occurrence and progression of the disease, rather than a way to reverse the disease.
Other disease-modifying approaches available include targeting the hyperphosphorylated-tau-laden tangles with specific kinase inhibitors, strengthening the microtubule network that breaks down as a result of tau hyperphosphorylation, or directly breaking up tau aggregates with compounds such as methylene blue. 49 In addition, it may be possible to protect neurons and synapses from the effects of either the Aβ peptide or hyperphosphorylated tau, such that synaptic and neuronal loss does not occur even in the presence of plaques and tangles. For example, it is known that many cognitively normal people have plaques and tangles in their brains, 14 which could be a form of pre-symptomatic AD, or these people may harbor some innate protection against these pathologies, such as a muted inflammatory response. 50 Such therapies will likely target either the inflammatory system, as chronic elevated inflammation can lead to neurodegeneration, or neuronal calcium signaling, as increased localized calcium levels could lead to both synaptic and neuronal degeneration and have been
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measured in transgenic mouse models of the disease. 51 As a partial NMDA receptor antagonist, memantine may protect against synaptic toxicity in AD and confer relief against the disease through a reduction in synaptic calcium levels.
52

Conclusions
It is becoming increasingly apparent that treatments for AD must be administered as early in the disease process as possible in order to be effective. Unfortunately, until pre-clinical biomarkers for AD are discovered and developed, this remains a difficult feat. It is also unlikely that such a complex disease will be treated or prevented with a single therapy. More likely, combinations of treatments will prove most effective either through additive effects, for example by reducing Aβ generation, or through combining disease modification with symptomatic relief and perhaps neurotrophin therapies. 
